Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
APDN

APDN - Applied DNA Sciences Inc Stock Price, Fair Value and News

0.40USD-0.01 (-2.44%)Delayed

Market Summary

APDN
USD0.40-0.01
Delayed
-2.44%

APDN Stock Price

View Fullscreen

APDN RSI Chart

APDN Valuation

Market Cap

393.9K

Price/Earnings (Trailing)

-0.03

Price/Sales (Trailing)

0.07

EV/EBITDA

0.25

Price/Free Cashflow

-0.04

APDN Price/Sales (Trailing)

APDN Profitability

Operating Margin

33.98%

EBT Margin

-223.89%

Return on Equity

7.0K%

Return on Assets

-133.97%

Free Cashflow Yield

-2.3K%

APDN Fundamentals

APDN Revenue

Revenue (TTM)

5.5M

Rev. Growth (Yr)

-78.91%

Rev. Growth (Qtr)

4.32%

APDN Earnings

Earnings (TTM)

-12.3M

Earnings Growth (Yr)

-859.84%

Earnings Growth (Qtr)

-295.52%

Breaking Down APDN Revenue

Last 7 days

-7.0%

Last 30 days

-13.0%

Last 90 days

-94.1%

Trailing 12 Months

-71.6%

How does APDN drawdown profile look like?

APDN Financial Health

Current Ratio

1.66

APDN Investor Care

Buy Backs (1Y)

92.37%

Diluted EPS (TTM)

-6.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20245.5M000
202317.5M16.1M13.4M9.0M
202215.1M17.6M18.2M19.3M
20215.0M6.3M9.0M11.6M
20204.9M3.3M1.9M2.9M
20193.9M4.9M5.4M5.1M
20184.6M3.9M3.9M4.1M
20174.1M5.2M4.8M4.5M
20168.1M6.5M4.2M3.8M
20154.2M5.7M9.0M9.1M
20142.6M2.8M2.7M3.4M
20131.5M1.6M2.0M2.3M
20121.5M1.8M1.9M1.7M
2011744.3K856.6K968.8K1.2M
201000519.8K632.1K

Tracking the Latest Insider Buys and Sells of Applied DNA Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 23, 2023
shorrock clay
acquired
-
-
91,667
chief legal officer
Mar 23, 2023
jantzen beth
acquired
-
-
91,667
chief financial officer
Mar 23, 2023
murrah judith
acquired
-
-
99,306
cio and coo
Mar 10, 2021
anchin scott l
sold
-110,042
8.43301
-13,049
-
Mar 05, 2021
anchin scott l
acquired
56,240
4.30992
13,049
-
Jun 26, 2020
montgomery william w
bought
577,500
5.25
110,000
-
Jun 26, 2020
montgomery william w
bought
-692,000
8.65
-80,000
-
Jun 18, 2020
montgomery william w
bought
210,000
5.25
40,000
-
Jun 09, 2020
montgomery william w
bought
393,750
5.25
75,000
-
Jun 09, 2020
montgomery william w
bought
-316,560
7.914
-40,000
-

1–10 of 35

Which funds bought or sold APDN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
Dakota Community Bank & Trust NA
sold off
-100
-1.00
-
-%
Jul 12, 2024
Silverberg Bernstein Capital Management LLC
sold off
-100
-40,303
-
-%
Jul 09, 2024
MATHER GROUP, LLC.
new
-
287
287
-%
Jul 03, 2024
Glen Eagle Advisors, LLC
new
-
21.00
21.00
-%
Jun 20, 2024
HM PAYSON & CO
sold off
-100
-9,499
-
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
17,320
17,320
-%
May 15, 2024
Royal Bank of Canada
unchanged
-
-
1,000
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
added
74.19
33.00
243
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
new
-
531,358
531,358
0.01%
May 15, 2024
MORGAN STANLEY
unchanged
-
-135
270
-%

1–10 of 36

Are Funds Buying or Selling APDN?

Are funds buying APDN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APDN
No. of Funds

Unveiling Applied DNA Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 24, 2024
leviticus partners lp
7.21%
649,809
SC 13G/A
Jun 07, 2024
s.h.n. financial investments ltd.
9.99%
1,013,807
SC 13G
Jun 07, 2024
l1 capital global opportunities master fund, ltd.
9.99%
1,021,000
SC 13G
Jun 03, 2024
leviticus partners lp
5.59%
571,232
SC 13G/A
May 01, 2024
leviticus partners lp
9.27%
80,000
SC 13G
Feb 12, 2024
grossman bruce
9.8%
1,666,798
SC 13G
Jan 10, 2024
awm investment company, inc.
3.5%
5e+05
SC 13G/A
Feb 14, 2023
awm investment company, inc.
9.99%
720,942
SC 13G
Feb 09, 2023
grossman bruce
4.9%
658,739
SC 13G/A
Feb 14, 2022
hayward james a
6.45%
506,481
SC 13D

Recent SEC filings of Applied DNA Sciences Inc

View All Filings
Date Filed Form Type Document
Jul 15, 2024
8-K
Current Report
Jun 28, 2024
8-K
Current Report
Jun 25, 2024
DEFA14A
DEFA14A
Jun 24, 2024
SC 13G/A
Major Ownership Report
Jun 21, 2024
DEF 14A
DEF 14A
Jun 18, 2024
8-K
Current Report
Jun 10, 2024
PRE 14A
PRE 14A
Jun 07, 2024
SC 13G
Major Ownership Report
Jun 07, 2024
SC 13G
Major Ownership Report
Jun 03, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Applied DNA Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
23.7B
-5.41% 12.43%
40.98
7.6
-8.94% -35.91%
38.7B
3.7B
-7.03% -13.75%
44.62
10.38
8.57% 23.94%
38.5B
6.6B
-2.30% 5.82%
30.96
5.83
-6.38% -8.07%
16.2B
9.3B
6.34% 1.67%
19.17
1.75
-3.29% 6.68%
13.0B
2.0B
4.50% 70.57%
41.75
6.65
25.57% 21.62%
13.0B
1.2B
-1.84% 123.25%
-35.62
10.77
39.26% 33.08%
11.2B
4.1B
4.05% 7.02%
25.3
2.73
0.49% -10.45%
MID-CAP
8.6B
2.5B
11.64% -50.70%
-35.95
3.41
15.21% 53.51%
3.8B
603.7M
2.74% -17.56%
-8.17
6.23
25.21% 30.68%
3.5B
929.2M
-2.97% -26.96%
2.3K
3.81
28.93% 111.61%
SMALL-CAP
942.7M
275.1M
28.64% 80.46%
-5.15
3.43
-13.93% -126.97%
94.1M
31.1M
16.81% -87.36%
-1.22
3.02
0.95% 19.75%
18.8M
9.0M
-7.93% -45.09%
-1.28
2.09
4.46% 45.80%
393.9K
5.5M
-13.04% -71.63%
-0.03
0.07
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Applied DNA Sciences Inc News

Latest updates
StockTitan18 Jul 202402:00 pm
Investing.com15 Jul 202408:55 pm
American Banking and Market News15 Jul 202405:30 am

Applied DNA Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.3%929,631891,164779,7362,917,3414,407,6145,262,7523,559,3174,296,3716,147,2834,165,7063,039,7351,700,3202,671,5421,616,141313,989431,516552,473633,5191,672,8422,053,457778,468
Cost Of Revenue-4.0%633,980660,067700,7401,648,0232,600,1792,885,0693,142,5583,257,1133,658,7983,056,5681,972,3771,116,106940,568515,781154,483154,804179,582232,031320,105270,883133,141
Gross Profit27.9%295,651231,09778,9961,269,3181,807,4352,377,683416,7591,039,2582,488,4851,109,1381,067,358584,2141,730,9741,100,360-------
Operating Expenses-2.7%3,913,4024,020,1634,249,9964,128,4274,511,4593,596,6614,669,0653,895,9024,642,7215,815,7155,652,7204,025,9234,046,9654,073,4624,105,1623,465,5063,055,0993,012,9063,216,5823,214,2063,277,964
  S&GA Expenses-2.7%3,000,2083,084,3483,311,0893,292,3043,522,7152,625,3573,756,1843,032,8773,572,6804,735,6193,528,2022,883,8123,091,2273,309,6542,783,1812,589,0422,285,5442,373,4132,259,5292,407,2232,528,914
  R&D Expenses-2.4%913,194935,815938,907836,123988,744971,304912,881863,0251,070,0411,080,0961,302,7771,142,111955,738763,8081,239,720814,599703,018564,426886,669719,668651,377
EBITDA Margin-206.9%-2.01-0.65-0.64-0.35-0.21-0.32-0.38-0.61-0.88-1.13-1.49-2.11---------
Interest Expenses-53.9%15,35233,32341,22426,7833,6393,6861,387-5,5402731,7003,57213,841-5,438-29,019-28,624-29,096-29,091-55,226-38,177-37,417
Income Taxes-------------------15,000--
Earnings Before Taxes-297.6%-4,493,783-1,130,281-3,615,651-3,114,195551,176-3,844,246-664,554-1,124,796-1,759,797-4,720,911-4,507,584-3,446,715-1,517,078-4,807,062-4,125,146-3,290,112-2,950,905-2,662,741-1,218,458-1,477,911-2,686,757
EBT Margin-175.6%-2.24-0.81-0.75-0.44-0.29-0.38-0.46-0.69-0.96-1.23-1.58-2.21---------
Net Income-295.5%-4,470,474-1,130,281-3,591,827-3,099,766588,343-3,844,246-663,091-1,124,220-1,759,797-4,720,911-4,512,201-3,448,993-1,517,078-4,807,062-4,123,528-3,289,450-2,950,905-2,662,741-1,224,135-1,477,911-2,686,757
Net Income Margin-177.0%-2.23-0.80-0.74-0.43-0.29-0.38-0.46-0.69-0.96-1.23-1.58-2.21---------
Free Cashflow14.6%-3,209,906-3,757,592-2,679,679-1,393,389160,049-2,383,106-3,501,281-1,830,981-327,417-3,806,580-5,618,495-1,752,554---------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.4%9,1769,91313,65215,79019,17520,29722,26511,92013,87911,40214,41717,19020,7829,67811,34113,97511,32710,8723,5652,9854,226
  Current Assets-4.9%4,3654,5908,12712,24015,38018,33219,9439,26811,1568,49911,29813,69617,4196,5409,07812,1559,9799,6382,1461,6052,763
    Cash Equivalents-6.2%3,1503,3597,15210,75613,03712,87715,2154,6826,5132,7486,55512,17313,9264,2417,78710,9258,6638,6635595071,541
  Inventory-11.0%3363773302763664776021,1721,4111,3011,37042972154349744589.0083.00143310315
  Net PPE-31.8%3685398381,1681,5751,8662,2232,5572,6292,8083,0242,5772,4232,1751,278751265184226265316
  Goodwill------------285285285285285285285285285285
Liabilities61.6%9,3515,7858,7798,5959,20711,1399,3565,1266,2333,0103,3041,6062,1623,9555,6325,1964,0583,6484,4134,7744,960
  Current Liabilities1.4%2,6232,5882,8452,8913,6553,3304,1854,2843,6332,9793,2721,5752,1302,9194,2662,4481,8501,5092,2461,9742,220
Shareholder's Equity-104.2%-1754,1284,9517,2499,9689,15812,9096,7957,6478,39211,11315,58418,6205,7235,7108,7797,2697,224---
  Retained Earnings-1.5%-308,255-303,630-302,447-298,854-295,755-296,343-292,500-291,836-290,712-288,843-284,122-279,611-276,162-274,645-269,835-265,712-262,423-259,471-256,805-255,271-253,793
  Additional Paid-In Capital0.1%308,207307,849307,398306,091305,751305,493305,399298,624298,352297,228295,228295,191294,781280,369275,549274,493269,694266,699255,963253,445253,022
Shares Outstanding-95.0%68313,659-12,90964512,90912,9098,1857,7847,4867,4866,725---------
Minority Interest-22.4%-127-103-78.75-55.36-40.93-3.76-2.89-1.55-979*133*-722*-4.23-6.51-6.23-8.72-6.51-5.85-7.07-7.04--
Float-----14,400---17,200---45,800---13,500---21,000
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations14.6%-3,209-3,757-2,679-1,369214-2,383-3,258-1,754-261-3,701-4,712-1,249-3,270-4,155-2,983-3,008-2,420-2,731-3,059--2,288
  Share Based Compensation-49.8%17134134134025994.002732732731,70037.00410649571204365227205295154267
Cashflow From Investing----924-161-54.3445.00-242-76.67-65.53-104-906-502-810-329-1,007-11.43-44.75--3.45--11.93
Cashflow From Financing8696.8%3,015-35.08----14,03575*4,092---13,7659408525,2822,46510,8352,081-704
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

APDN Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Revenues    
Total revenues$ 929,631$ 4,407,614$ 1,820,795$ 9,670,366
Total cost of revenues633,9802,600,1791,294,0475,485,248
Gross profit295,6511,807,435526,7484,185,118
Operating expenses:    
Selling, general and administrative3,000,2083,522,7156,084,5576,148,072
Research and development913,194988,7441,849,0091,960,048
Total operating expenses3,913,4024,511,4597,933,5668,108,120
LOSS FROM OPERATIONS(3,617,751)(2,704,024)(7,406,818)(3,923,002)
Interest income15,3523,63948,6767,325
Unrealized gain on change in fair value of warrants classified as a liability1,765,0003,250,9004,404,000613,100
Unrealized (loss) on change in fair value of warrants classified as a liability - warrant modification(394,000) (394,000) 
Loss on issuance of warrants(1,633,767) (1,633,767) 
Transaction cost allocated to warrant liabilities(633,198) (633,198) 
Other income (expense), net4,581661(8,957)9,507
(Loss) income before provision for income taxes(4,493,783)551,176(5,624,064)(3,293,070)
NET (LOSS) INCOME(4,493,783)551,176(5,624,064)(3,293,070)
Less: Net loss attributable to noncontrolling interest23,30937,16748,49038,041
NET (LOSS) INCOME attributable to Applied DNA Sciences, Inc.(4,470,474)588,343(5,575,574)(3,255,029)
Deemed dividend related to warrant modifications(155,330) (233,087) 
NET (LOSS) INCOME attributable to common stockholders$ (4,625,804)$ 588,343$ (5,808,661)$ (3,255,029)
Net (loss) income per share attributable to common stockholders - basic (in dollars per share)$ (5.31)$ 0.91$ (7.47)$ (5.04)
Net (loss) income per share attributable to common stockholders - diluted (in dollars per share)$ (5.31)$ 0.91$ (7.47)$ (5.04)
Weighted average shares outstanding - basic (in shares)871,319645,426777,495645,426
Weighted average shares outstanding - diluted (in shares)871,319645,426777,495645,426
Product revenues    
Revenues    
Total revenues$ 393,125$ 297,454$ 700,442$ 813,850
Total cost of revenues340,301369,563622,846734,941
Service revenues    
Revenues    
Total revenues205,486169,058452,633401,119
Clinical laboratory service revenues    
Revenues    
Total revenues331,0203,941,102667,7208,455,397
Total cost of revenues$ 293,679$ 2,230,616$ 671,201$ 4,750,307

APDN Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2024
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 3,149,640$ 7,151,800
Accounts receivable, net of allowance for credit losses of $75,000 at March 31, 2024 and September 30, 2023, respectively408,853255,502
Inventories335,943330,027
Prepaid expenses and other current assets470,284389,241
Total current assets4,364,7208,126,570
Property and equipment, net367,821838,270
Other assets:  
Restricted cash750,000750,000
Intangible assets2,698,9752,698,975
Operating right of use asset994,1111,237,762
Total assets9,175,62713,651,577
Current liabilities:  
Accounts payable and accrued liabilities2,050,0352,270,388
Operating lease liability, current521,719498,598
Deferred revenue51,28576,435
Total current liabilities2,623,0392,845,421
Long term accrued liabilities31,46731,467
Deferred revenue, long term194,000194,000
Operating lease liability, long term472,391739,162
Deferred tax liability, net684,115684,115
Warrants classified as a liability5,346,0004,285,000
Total liabilities9,351,0128,779,165
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' (deficit) equity:  
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of March 31, 2024 and September 30, 2023, 863,068 and 682,926 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively864683
Additional paid in capital308,206,796307,397,623
Accumulated deficit(308,255,808)(302,447,147)
Applied DNA Sciences, Inc. stockholders' (deficit) equity(48,148)4,951,159
Noncontrolling interest(127,237)(78,747)
Total (deficit) equity(175,385)4,872,412
Total liabilities and (deficit) equity9,175,62713,651,577
Series A Preferred stock  
Applied DNA Sciences, Inc. stockholders' (deficit) equity:  
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively
Series B Preferred stock  
Applied DNA Sciences, Inc. stockholders' (deficit) equity:  
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively
APDN
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR)-based MDx testing services for the Monkeypox virus; and MDx test kits and related supplies, as well as validates pharmacogenetics (PGx) testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, leather, pharmaceuticals, nutraceuticals, and other products; SigNify IF portable DNA readers and SigNify consumable reagent test kits, which offers a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
 CEO
 WEBSITEadnas.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES61

Applied DNA Sciences Inc Frequently Asked Questions


What is the ticker symbol for Applied DNA Sciences Inc? What does APDN stand for in stocks?

APDN is the stock ticker symbol of Applied DNA Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied DNA Sciences Inc (APDN)?

As of Fri Jul 19 2024, market cap of Applied DNA Sciences Inc is 393.89 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APDN stock?

You can check APDN's fair value in chart for subscribers.

What is the fair value of APDN stock?

You can check APDN's fair value in chart for subscribers. The fair value of Applied DNA Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied DNA Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APDN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied DNA Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether APDN is over valued or under valued. Whether Applied DNA Sciences Inc is cheap or expensive depends on the assumptions which impact Applied DNA Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APDN.

What is Applied DNA Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, APDN's PE ratio (Price to Earnings) is -0.03 and Price to Sales (PS) ratio is 0.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APDN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Applied DNA Sciences Inc's stock?

In the past 10 years, Applied DNA Sciences Inc has provided -0.478 (multiply by 100 for percentage) rate of return.